Alpha 1 Antitrypsin Phenotype Identification EQA
| Accreditation Status: | UKAS Schedule of Accreditation | ||||||||
| Date Scheme started: | 2007 | ||||||||
| Clinical Applicability: |
The quantitation of AAT is indicated in the evaluation of chronic obstructive airway disease (COPD), emphysema and in neonatal and adult liver disease where low concentrations may have diagnostic importance. AAT genetic status (PI phenotyping) should be performed in all cases of deficiency when the quantitative assay gives results below the age related median concentration. The PI phenotyping should be determined in all children with liver disease irrespective of AAT concentration. |
||||||||
| Analytes: |
Alpha 1 Antitrypsin, PI Phenotyping (SER/037) The sample analytes included will depend on their prevalence in the general population, therefore not all analytes may be covered during the year. |
||||||||
| Units for Reporting: | g/L | ||||||||
| Samples Distributed: | Liquid format. Normal and pathological human serum | ||||||||
| Number of Distributions per year: | 4 | ||||||||
| Number of Samples per Distribution: | 2 | ||||||||
| Frequency of Distributions: | Every three months as outlined in the Distribution Schedule | ||||||||
| Schedule of Analysis: | Data entry is via the web for the submission of results. Data analysis commences 28 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics. | ||||||||
| Data Analysis: |
Phenotype Identification responses are assessed by MI scoring in relation to the designated response. |
||||||||
| Performance Scoring: | MI scoring | ||||||||
| Criteria of Performance: |
Laboratory performance is assessed over a running analytical window of 4 Distributions (12 months)
|
||||||||
| Persistent Poor Performance: |
Defined as being in the Poor Performance category for two or more successive Distributions |